Study finds paxlovid treatment does not reduce risk of long COVID

A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection. They also found a higher proportion of individuals with acute symptoms rebound and test-positivity than previously reported. The study appears Jan. 4, 2024, in the Journal of Medical Virology. Paxlovid treatment […]

Paxlovid associated with lower risk of hospital admission

A Kaiser Permanente study confirms the benefit of nirmatrelvir-ritonavir, also known as Paxlovid, as an early-stage treatment to prevent hospitalization for people with mild to moderate COVID-19, regardless of prior immunity or age. The study was published March 15, 2023, in Lancet ID. “Among Kaiser Permanente members in Southern California who tested positive for coronavirus infection, receiving Paxlovid within 5 […]